Journal of Nutrition Bio-Serv Delivering Solutions. . .

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakagawa, K.
Right arrow Articles by Miyazawa, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakagawa, K.
Right arrow Articles by Miyazawa, T.
© 2007 American Society for Nutrition J. Nutr. 137:1938-1943, August 2007

Nutrition and Disease

In Vivo Angiogenesis Is Suppressed by Unsaturated Vitamin E, Tocotrienol1,2

Kiyotaka Nakagawa3, Akira Shibata3, Shinji Yamashita3, Tsuyoshi Tsuzuki3,4, Jun Kariya5, Shinichi Oikawa6 and Teruo Miyazawa3,*

3 Food and Biodynamic Chemistry Laboratory, Graduate School of Agricultural Science, Tohoku University, Sendai 981-8555, Japan; 4 Department of Food Management, School of Food, Agricultural and Environment Sciences, Miyagi University, Sendai 982-0215, Japan; 5 Project M Co. Ltd., Sendai 980-0014, Japan; and 6 Department of Medicine, Nippon Medical School, Tokyo 113-8603, Japan

* To whom correspondence should be addressed. E-mail: miyazawa{at}biochem.tohoku.ac.jp.


   ABSTRACT
TOP
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 LITERATURE CITED
 
Antiangiogenic therapy using drugs and food components is a recognized strategy for the prevention of various angiogenesis-mediated disorders such as tumor growth, diabetic retinopathy, and rheumatoid arthritis. Our preliminary cell culture studies, using both bovine aortic endothelial cells and human umbilical vein endothelial cells (HUVEC) on screening for food-derived antiangiogenic compounds, showed tocotrienol (T3), an unsaturated version of vitamin E, to be a potential angiogenic inhibitor. We therefore investigaged the in vivo antiangiogenic properties of T3 using 2 well-characterized angiogenic models [mouse dorsal air sac (DAS) assay and the chick embryo chorioallantoic membrane (CAM) assay]. In the DAS assay, the increased neovascularization (angiogenesis index, 4.8 ± 0.6) in tumor cell–implanted mice was suppressed (angiogenesis index, 2.7 ± 0.6) by dietary supplementation of 10 mg T3-rich oil/d (equivalent to 4.4 mg T3/d). In the CAM assay, T3 (500–1000 µg/egg) inhibited new blood vessel formation on the growing CAM and increased the frequency of avascular zone (36–50%). To evaluate the antiangiogenic mechanism, we conducted cell-culture studies and found that T3 significantly reduced fibroblast growth factor -induced proliferation, migration, and tube formation in HUVEC (P < 0.05), with {delta}-T3 having the highest activity. Western blot analysis revealed that {delta}-T3 suppressed the phosphorylation of phosophoinositide-dependent protein kinase (PDK) and Akt, and increased the phosphorylation of apoptosis signal-regulating kinase and p38 in fibroblast growth factor-treated HUVEC, indicating that the antiangiogenic effects of T3 are associated with changes in growth factor-dependent phosphatidylinositol-3 kinase /PDK/Akt signaling as well as induction of apoptosis in endothelial cells. Our findings suggest that T3 has potential as a therapeutic dietary supplement for preventing angiogenic disorders, and therefore future clinical study will be required to evaluate the efficacy and safety of T3.


   Introduction
TOP
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 LITERATURE CITED
 
Vitamin E occurs naturally in 8 different forms: {alpha}-, ß-, {gamma}-, and {delta}-isomers of both tocopherol (Toc)7 and tocotrienol (T3) (Fig. 1). They differ structurally in that Toc has a saturated phytyl side chain attached to its chroman ring, whereas T3 possesses an unsaturated isoprenoid side chain. Toc is abundant in common vegetable oils and nuts, and T3, a minor plant constituent, is abundant in rice bran, palm, and wheat germ (1,2).


Figure 1
View larger version (8K):
[in this window]
[in a new window]

  		FIGURE 1  Chemical structure of T3. T3 has an unsaturated isoprenoid tail, which differs from Toc bearing a saturated phytyl side-chain.

 
Recent studies indicate that T3 has better antioxidative (3,4), antihypercholesterolemic (5), anticancer (6), and neuroprotective (7,8) activities than Toc. Further, the potent ability of T3 to induce cell cycle arrest (9), regulate HMG-CoA reductase (5), activate p53 and caspase-8 (10,11), suppress adhesion molecules (12), inhibit nuclear factor-{kappa}B (13), and downregulate c-Myc and telomerase (14) was reported. These studies (3–14) suggest that T3 may serve as a food component with a wide variety of health benefits.

In our own recent cell culture studies (15–17), T3 suppressed angiogenesis by inhibiting proliferation, migration, and tube formation of endothelial cells. Angiogenesis, or new blood vessel growth from an existing vasculature, has become a promising target for experimental therapies in pathological states (e.g., diabetic retinopathy, rheumatoid arthritis, and tumor growth) (18,19). Although physiological conditions (e.g., reproductive cycles and wound healing) are angiogenesis dependent (20), more than 20 angiogenesis inhibitors are registered by the National Cancer Institute, including metalloproteinase inhibitors in early phases of clinical trials in the treatment of cancer (21). Considering this background, T3 may be used as a potential antiangiogenic compound in the prevention of angiogenesis-mediated disorders. Therefore, the evaluation for in vivo antiangiogenic efficacy and mechanism of T3 is important for understanding the physiological impact (benefits as well as risks) of dietary exposure to T3.

We investigated the in vivo antiangiogenic properties of T3 using 2 well-characterized angiogenic systems [mouse dorsal air sac (DAS) assay and the chick embryo chorioallantoic membrane (CAM) assay] . The antiangiogenic mechanism of T3 was evaluated in the cell culture using Western blot analysis.


   Materials and Methods
TOP
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 LITERATURE CITED
 
    Materials. T3 was purchased from Calbiochem, Toc was obtained from Sigma, and Tocomin 50 (T3 extract from palm oil) was kindly supplied by Koyo Mercantile. Tocomin 50 was composed of 14% {alpha}-Toc (wt:wt) and 44% T3 (14% {alpha}-T3, 24% {gamma}-T3, and 6% {delta}-T3). The vitamin E–free AIN-76 diet (22) was from Funahashi Farm. Vitamin E–stripped corn oil was purchased from ICN Biomedicals.

    Animals and cells. Four-week–old male ICR mice were obtained from CLEA and housed in cages maintained at 23°C with a 12-h light:12-h dark cycle. They were acclimatized to a vitamin E-free AIN-76 diet (22) and water for 1 wk.

Human colorectal adenocarcinoma cells (DLD-1) were obtained from the Cell Resource Center for Biomedical Research at the Tohoku University School of Medicine. The cells were maintained in RPMI-1640 medium (containing 0.3 g/L L-glutamine and 2.0 g/L sodium bicarbonate; Sigma) supplemented with 10% fetal bovine serum (FBS) (Dainippon Pharmaceutical), 100 kU/L penicillin (Gibco BRL), and 100 mg/L streptomycin (Gibco BRL) at 37°C in a humidified atmosphere containing 5% CO2. Human umbilical vein endothelial cells (HUVEC) were purchased from Kurabo. HUVEC were cultured in growth medium HuMedia-EG2 (Kurabo), which consisted of base medium (HuMedia-EB2) supplemented with 2% FBS, 10 µg/L human epidermal growth factor, 5 mg/L human basic fibroblast growth factor (FGF), 10 mg/L heparin, 1 mg/L hydrocortisone, 50 mg/L gentamicin, and 50 µg/L amphotericin B. Confluent HUVEC cells (passages 4–8) were used for the experiments.

    In vivo study of angiogenesis inhibition by T3. The in vivo effects of T3 on tumor cell-induced angiogenesis were evaluated using the DAS assay (23). DLD-1 cells (1 x 107 cells) were resuspended in 0.1 mL of PBS. The cell suspension was injected into a chamber ring (Millipore) and packed with a filter (0.45 µm pore size). The chamber filled with DLD-1 cells was then surgically implanted into a subcutaneous dorsal air sac produced by preinjection of 10 mL air into an ICR mouse. The treated mice were fed 2.5 mg of Tocomin 50 (0.35 mg {alpha}-T3, 0.60 mg {gamma}-T3, 0.15 mg {delta}-T3, and 0.35 mg {alpha}-Toc), 10 mg of Tocomin 50 (1.4 mg {alpha}-T3, 2.4 mg {gamma}-T3, 0.60 mg {delta}-T3, and 1.4 mg {alpha}-Toc), or 1.5 mg {alpha}-Toc once a day for 5 d by gavage using 50 mg vitamin E–stripped corn oil (ICN Biomedicals) as a vehicle. Control mice received only the vehicle (vitamin E–stripped corn oil). During the feeding period, the mice were allowed free access to the vitamin E–free AIN-76 diet (22) and water. The mice were then killed with sodium pentobarbital, and their skins were removed. Numbers of new blood vessels (longer than 3 mm and showing a zig-zag pattern) within the area attached to the chamber were counted and scored as the angiogenesis index. Angiogenesis indices of 0, 1, 2, 3, 4, and 5 indicated that the number of neovessels was 0, 1, 2, 3, 4, and > 5, respectively. This experiment was conducted in compliance with the policies and procedures detailed in the Animal Experiment Guidelines of Tohoku University.

The CAM assay (24) was performed to further evaluate in vivo antiangiogenic activities of T3. A pellet of ethylene-vinyl acetate copolymer 40 (Aldrich Chemical) impregnated with {delta}-T3 (0–1000 µg), {alpha}-Toc (0–1000 µg), or without vitamin E (control) was placed on the CAM surface of 5-d–old chick embryos. The embryos were incubated for 2 d at 37°C in a humidified incubator, after which an appropriate volume of 10% fat emulsion was injected into the chorioallantois to improve visualization of the vascular network. Inhibition of angiogenesis was determined by measuring the avascular zone in the CAM. A positive antiangiogenic response was defined as an avascular zone of ≥3 mm in diameter.

    In vitro study of angiogenesis inhibition by T3. The in vitro effect of T3 on FGF-induced proliferation, migration, and tube formation of HUVEC was investigated as follows.

For the proliferation assay, the HUVEC were transferred into 96-well plates (2500 cells/well) and preincubated in HuMedia-EG2 medium for 24 h. After the HUVEC were washed with PBS, the culture medium was replaced with test medium (HuMedia-EB2 supplemented with 2% FBS, 10 µg/L FGF, and 0–35 µmol/L T3). After incubating for 72 h, viable cells were estimated using the water-soluble tetrazolium salt assay (25), which measures the metabolic activity of viable cells by the formation of a formazan dye.

For the migration assay, confluent HUVEC were cultured in 24-well collagen type 1-coated culture plates in HuMedia-EG2 medium without growth factors. After 12 h, the cells were scratched with a yellow pipette tip to obtain a wounded monolayer culture (26). After washing with PBS, the cells were cultured for 36 h in the test medium (HuMedia-EB2 with 10 µg/L FGF and 0–7 µmol/L {delta}-T3). Cell migration was recorded as the lengths of wounded cells using a phase contrast inverted microscope.

In the tube formation assay, culture plates (24-well) were coated with 350 µL of Matrigel (Becton Dickinson) and incubated at 37°C for 1 h to allow solidification. Trypsin-harvested HUVEC (6 x 104 cells) were suspended in 500 µL of test medium (HuMedia-EB2 with 1% FBS, 10 µg/L FGF, and 0–7 µmol/L {delta}-T3). The cell suspension was placed on the surface of Matrigel, and was incubated for 18 h. After that, the cells were fixed and then photographed. The length of tube-structured cells was quantified using a Kurabo angiogenesis Image Analyzer (imaging software; Kurabo).

    Antiangiogenic mechanism of T3 evaluated by Western blot analysis. HUVEC were treated with T3 under 2 different conditions; 1) 24-h incubation with 10 µg/L FGF and 0–7 µmol/L {delta}-T3 in HuMedia-EB2 medium with 2% FBS, or 2) 10-min stimulation with 10 µg/L FGF after preincubation for 8 h in HuMedia-EB2 medium with 2% FBS and 0–7 µmol/L {delta}-T3. After that, cellular proteins were prepared from HUVEC as previously described (27), and the cellular proteins (50 µg/well) were separated by SDS-PAGE gel electrophoresis (10–20% e-PAGEL, Atto). The protein bands were transferred to polyvinylidine fluoride membrane (Amersham Pharmacia Biotech). After being blocked of nonspecific sites, the membrane was probed with primary antibodies, followed by a horseradish peroxidase-conjugated secondary antibody (Cell Signaling Technology). The detection of the antibody reactions was performed with ECL Plus Western blotting reagents (Amersham Pharmacia Biotech). The antibodies used were anti-Cyclin D1 and anti-ß-Actin (Santa Cruz Biotechnology); anti-phospho phosophoinositide-dependent protein kinase (PDK), anti-phospho Akt, anti-phospho extracellular signal-regulated kinase 1/2 (ERK 1/2), anti-phospho p38, anti-phospho apoptosis signal-regulating kinase (ASK-1), anti-phospho glycogen synthase kinase 3 {alpha}/ß (GSK3 {alpha}/ß), and anti-phospho endothelial nitric oxide synthase (eNOS) (Cell Signaling Technology); anti-Caspase 9 (Medical Biological Laboratories); anti-Caspase 3 (Neomarkers); and anti-p21 (Upstate Biotechnology).

    Statistical analysis. The data are expressed as mean ± SD unless otherwise indicated and were tested by 1-way ANOVA, followed by Newman-Keules test. For the CAM assay, Fisher's exact probability test was performed. Differences were considered significant at P < 0.05.


   Results
TOP
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 LITERATURE CITED
 
We first conducted a DAS assay to evaluate the in vivo effect of Tocomin 50 (T3-rich oil) on DLD-1 induced angiogenesis (Fig. 2). The DLD-1 chamber implanted control mice showed remarkable neovascularization from surrounding blood vessels. Vessel formation was clearly suppressed in mice given Tocomin 50 orally at a dose of 10 mg/d (1.4 mg {alpha}-T3, 2.4 mg {gamma}-T3, 0.6 mg {delta}-T3, and 1.4 mg {alpha}-Toc). Because {alpha}-Toc (1.5 mg/d) showed no angiogenic inhibition, the antiangiogenic effect of Tocomin 50 could be mainly ascribed to T3. We further examined the in vivo effect of T3 on angiogenesis using the CAM assay (Fig. 3). T3-free pellets (ethylene-vinyl acetate copolymer) did not exhibit any antiangiogenic effects. {delta}-T3, which was the most potent antiangiogenic T3 isomer in our previous in vitro studies (15–17), caused a suppression of embryonic angiogenesis, resulting in avascular zone. No antiangiogenic activity was found in {alpha}-Toc-treated CAM.


Figure 2
View larger version (62K):
[in this window]
[in a new window]

  		FIGURE 2  Effects of Tocomin 50 on tumor cell-induced angiogenesis in DLD-1 chamber implanted mice fed Tocomin 50 (2.5 and 10 mg) or {alpha}-Toc (1.5 mg) once a day for 5 d by gavage. Control mice received only the vehicle (vitamin E-stripped corn oil). Implanted chambers were removed and photographed (A) and numbers of new blood vessels counted and scored as the angiogenesis index (B). Values are mean ± SD, n = 10–12. Means without a common letter differ, P < 0.05.

 

Figure 3
View larger version (76K):
[in this window]
[in a new window]

  		FIGURE 3  Effects of T3 on the new blood vessel formation of the CAM. A pellet impregnated with {delta}-T3 (0–1000 µg), {alpha}-Toc (0–1000 µg) or without these vitamin E (control) was placed on the CAM and incubated for 2 d. The CAM was photographed (A) and the angiogenic response was evaluated by measuring the avascular zone (B). The number of eggs with avascular zones over the total number of eggs (n = 12–14) was presented. Means without a common letter differ, P < 0.05.

 
Because growth factors (i.e., FGF) are closely involved in the neovascularization of DAS and CAM models as well as pathological angiogenesis (18,19), we conducted a series of in vitro studies (FGF-induced proliferation, migration, and tube formation in HUVEC) to evaluate the antiangiogenic effects and inhibitory mechanism of T3 on FGF action. All T3 isomers inhibited FGF-induced HUVEC proliferation (Fig. 4). The median (±SD) concentrations resulting in 50% inhibition (IC50) of T3 isomers were: {delta}-T3 (5.5 ± 0.1 µmol/L), ß-T3 (9.4 ± 0.2 µmol/L), {gamma}-T3 (9.4 ± 0.2 µmol/L), and {alpha}-T3 (13.1 ± 0.2 µmol/L). {delta}-T3 inhibited HUVEC migration and reduced the length of endothelial tubes (Fig. 5). Western blot analysis indicated that {delta}-T3 suppressed the phosphorylation of PDK, Akt, ERK1/2, eNOS, and GSK3 {alpha}/ß, as well as increased the expression of p21 and the phosphorylation of ASK-1 and p38 in FGF-treated HUVEC (Fig. 6). Furthermore, at a relatively high concentration (7 µmol/L), {delta}-T3 cleaved procaspase-3 and procaspase-9 to their active forms and decreased Cyclin D1.


Figure 4
View larger version (34K):
[in this window]
[in a new window]

  		FIGURE 4  Effects of T3 on FGF-induced HUVEC proliferation. HUVEC were cultured with 0–35 µmol/L T3 in the presence of 10 µg/L FGF for 72 h. Viable cells were estimated using the water-soluble tetrazolium salt (WST-1) assay. Values are mean ± SD, n = 6. Means without a common letter differ, P < 0.05.

 

Figure 5
View larger version (39K):
[in this window]
[in a new window]

  		FIGURE 5  Effects of {delta}-T3 on FGF-induced HUVEC migration and tube formation. In the migration assay (A), HUVEC monolayers were sheared, followed by exposure to a test medium containing 10 µg/L FGF and 0–7 µmol/L {delta}-T3. After 36 h, the lengths of wounded cells were measured. Values are mean ± SD, n = 6. Means without a common letter differ, P < 0.05. In the tube formation assay (B), HUVEC were suspended in test medium containing 10 µg/L FGF and 0–7 µmol/L {delta}-T3, and placed on the surface of Matrigel. After incubation for 18 h, the tube lengths were quantified. Values are mean ± SD, n = 4. Means without a common letter differ, P < 0.05.

 

Figure 6
View larger version (48K):
[in this window]
[in a new window]

  		FIGURE 6  Western blot analysis of the intracellular proteins associated with the PI3K/PDK/Akt pathway and apoptosis. HUVEC were treated with T3 under 2 different conditions; (A) 24 h incubation with 10 µg/L FGF and 0–7 µmol/L {delta}-T3, or (B) 10 min stimulation with 10 µg/L FGF after preincubation with 0–7 µmol/L {delta}-T3 for 8 h. Each Western blot is a representative example of data from 3 replicate experiments.

 

   Discussion
TOP
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
LITERATURE CITED
 
Angiogenesis, the formation of new blood vessels, plays an important role in many pathological processes, such as the growth and metastasis of solid tumors, diabetic retinopathy, rheumatoid arthritis, and psoriasis (18,19). Because angiogenic processes are involved in endothelial cell proliferation, migration, and tube formation, the modulation of these processes serves as a good strategy for preventing angiogenesis-mediated disorders. It has been documented that some antiangiogenic agents are available in foods (28–33). Even if these agents possess moderate antiangiogenic effects, daily consumption of these compounds may help to prevent angiogenic disorders. Our preliminary cell-culture studies, which screened for food-derived antiangiogenic compounds, showed T3 to be a potential angiogenic inhibitor (15–17). We demonstrated, to our knowledge for the first time, that T3 exerts antiangiogenic effects in vivo. The antiangiogenic effects of T3 would be associated with changes in phosphatidylinositol-3 kinase (PI3K)/PDK/Akt signaling as well as apoptosis induction in endothelial cells.

One of the problems faced by angiogenesis researchers has been the difficulty in finding suitable methods for assessing the in vivo effects of angiogenic regulators (34). We chose 2 common and reliable methods for evaluating the antiangiogenic effects of T3 in the in vivo study: the DAS and CAM assays. The advantages of the DAS assay were that it is technically simple and also provides a natural environment in which to study blood vessels (23). The CAM assay is widely used in vivo to study angiogenesis (24). In the DAS assay, neovascularization of mouse subcutaneous tissues, which was triggered by DLD-1 cells, was effectively inhibited by the oral administration of Tocomin 50 (T3-rich oil) (Fig. 2). We found no negative effects in preexisting vessels treated with Tocomin 50. The results clearly suggested the notable in vivo antiangiogenic effects of T3. The calculated effective dose of T3 (150 mg/kg mouse/d) was lower than or similar to the reported dose associated with anticancer activities of T3 in murine experiments (35). We speculated that a substantial amount of T3 would be absorbed from mouse intestine and distributed to the tissues surrounding the DLD-1 chamber, where T3 can inhibit the vascularization of the cells bearing growth factor receptors, such as endothelial cells, smooth muscle cells, and the others responsible for neovascularization. However, there is little possibility for a direct effect of T3 on DLD-1 cells in the DAS assay. CAM assay was therefore performed for further evaluation of in vivo antiangiogenic activity of T3. T3 treatment of CAM resulted in an inhibition of the angiogenic response (Fig. 3), which occurred in the absence of any effects on embryo viability, suggesting very little toxicity from T3 in vivo. Because 4- to 6-d–old chick embryos do not have established mature immune responses (36), the observed antiangiogenesis effects of T3 in CAM were presumably mediated by direct inhibition of endothelial cell function. Considering both the DAS and CAM results, we concluded that T3 exerts antiangiogenic effects in vivo, potentiating the usability of T3 as a therapeutic dietary supplement for preventing angiogenic disorders (e.g., the inhibition of tumor growth and metastasis by disrupting angiogenesis). In one of our animal studies, orally administrated T3 to rats was found to be distributed in their blood stream and various tissues (37). This data would be advantageous for application of T3 in the use for functional and nutraceutical purposes. Because human life would not be possible without angiogenesis (20) and the dietary supplementation of vitamin E (Toc) increases bleeding tendency (38), future therapeutic applications of T3 should be developed with minimal toxicities except during times of wound healing, inflammation, ovulation, pregnancy, ischemia, hypertension, or other diseases associated with bleeding.

How T3 mediates its antiangiogenic effects is not fully understood, although its ability to suppress the growth factor-dependent activation of PI3K/PDK/Akt signaling in neoplastic mammary cells (39) has been reported. PI3K is a lipid signaling kinase that activates PDK, leading to activation of Akt, which in turn phosphorylates various intracellular substrates associated with cell proliferation and apoptosis (40). In contrast, various growth factors such as FGF are closely involved in neovascularization. FGF induces endothelial cells to secrete proteases and plasminogen activators that degrade the vessel basement membrane, leading to cell invasion into the surrounding matrix and the formation of new vessels (41). Considering the critical role of both PI3K/PDK/Akt signaling and antiapoptosis in growth factor–induced angiogenesis (42), we hypothesized that T3 must modulate angiogenesis through this pathway. To test this hypothesis, we conducted in vitro model studies (FGF-induced proliferation, migration, and tube formation of HUVEC) to evaluate the antiangiogenic effects and mechanisms of T3 action. We demonstrated that T3 reduced FGF-induced proliferation, migration, and tube formation in HUVEC (Figs. 4 and 5), and that these effects were related to a decrease in the intracellular protein activity associated with the PI3K/PDK/Akt pathway (Fig. 6). Our studies also showed that T3 at a relatively high dose (7 µmol/L) affected some proteins such as ASK-1 and p38 associated with apoptosis. In addition, T3 downregulated p21 and Cyclin D1, which are involved in cell cycle progression and arrest. Taken together, these results strongly suggest that angiogenesis inhibition by T3 is associated with changes in the PI3K/PDK/Akt signaling and apoptosis induction. DNA chip analysis supported the inhibitory mechanism of T3 (data not shown). Although the exact intracellular sites of action targeted by T3 were unknown, we postulated that the antiangiogenic effects of T3 occur upstream of the PI3K/PDK/Akt signaling pathway at the level of the growth factor receptor (e.g., suppression of FGF receptor tyrosine phosphorylation by T3). This possibility is still suggestive, so further studies are needed to clarify the mechanism.

In our study, T3 displays greater antiangiogenic activity than Toc in vivo and in vitro. Structurally, T3 and Toc can be distinguished by their side chains, and it has been reported that the unsaturated side chain of T3 allows it to pass through cell membranes more efficiently and at a faster rate than the saturated phytyl side-chain of Toc (43). For this reason, the greater antiangiogenic effect of T3 may be due in part to their effective incorporation into endothelial cells.

In conclusion, we demonstrated that T3 inhibits the angiogenic response in vivo and that this inhibitory effect is associated with changes in the PI3K/PDK/Akt signaling as well as by apoptosis induction in endothelial cells. Therefore, T3 has potential use as a functional compound for the prevention of angiogenic disorders.


   FOOTNOTES
 
1 This work was supported by a Grant-in-Aid from the Bio-oriented Technology Research Advancement Center of the National Agricultural and Biological Research Organization, Japan. Back

2 Author disclosures: K. Nakagawa, A. Shibata, S. Yamashita, T. Tsuzuki, J. Kariya, S. Oikawa, and T. Miyazawa, no conflicts of interest. Back

7 Abbreviations used: ASK-1, apoptosis signal-regulating kinase; CAM, chick embryo chorioallantoic membrane; DAS, dorsal air sac; DLD-1, human colorectal adenocarcinoma cell; FGF, fibroblast growth factor, FBS, fetal bovine serum; HUVEC, human umbilical vein endothelial cell; PDK, phosophoinositide-dependent protein kinase; PI3K, phosphatidylinositol-3 kinase; T3, tocotrienol; Toc, tocopherol. Back

Manuscript received 7 May 2007. Initial review completed 24 May 2007. Revision accepted 8 June 2007.


   LITERATURE CITED
TOP
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 LITERATURE CITED
 

1. Sundram K, Thiagarajan T, Gapor A, Basiron Y. Palm tocotrienols: new antioxidants for the new millennium. Inform. 2002;13:634–40.

2. Sookwong P, Nakagawa K, Murata K, Kojima Y, Miyazawa T. Quantitation of tocotrienol and tocopherol in various rice brans. J Agric Food Chem. 2007;55:461–5.[Medline]

3. Serbinova E, Kagan V, Han D, Packer L. Free radical recycling and intramembrane mobility in the antioxidant properties of {alpha}-tocopherol and {alpha}-tocotrienol. Free Radic Biol Med. 1991;10:263–75.[Medline]

4. Suzuki YJ, Tsuchiya M, Wassall SR, Choo YM, Govil G, Kagan VE, Packer L. Structural and dynamic membrane properties of {alpha}-tocopherol and {alpha}-tocotrienol: implication to the molecular mechanism of their antioxidant potency. Biochemistry. 1993;32:10692–9.[Medline]

5. Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993;268:11230–8.[Abstract/Free Full Text]

6. McIntyre BS, Briski KP, Gapor A, Sylvester PW. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med. 2000;224:292–301.[Abstract/Free Full Text]

7. Sen CK, Khanna S, Roy S, Packer L. Vitamin E sensitive genes in the developing rat fetal brain: a high-density oligonucleotide microarray analysis. J Biol Chem. 2000;275:13049–55.[Abstract/Free Full Text]

8. Khanna S, Roy S, Ryu H, Bahadduri P, Swaan PW, Ratan RR, Sen CK. Molecular basis of vitamin E action: tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration. J Biol Chem. 2003;278:43508–15.[Abstract/Free Full Text]

9. Wada S, Satomi Y, Murakoshi M, Noguchi N, Yoshikawa T, Nishino H. Tumor suppressive effects of tocotrienol in vivo and in vitro. Cancer Lett. 2005;229:181–91.[Medline]

10. Agarwal MK, Agarwal ML, Athar M, Gupta S. Tocotrienol-rich fraction of palm oil activates p53, modulates Bax/Bcl2 ratio and induces apoptosis independent of cell cycle association. Cell Cycle. 2004;3:205–11.[Medline]

11. Shah S, Sylvester PW. Tocotrienol-induced caspase-8 activation is unrelated to death receptor apoptotic signaling in neoplastic mammary epithelial cells. Exp Biol Med (Maywood). 2004;229:745–55.[Abstract/Free Full Text]

12. Theriault A, Chao JT, Gapor A. Tocotrienol is the most effective vitamin E for reducing endothelial expression of adhesion molecules and adhesion to monocytes. Atherosclerosis. 2002;160:21–30.[Medline]

13. Ahn KS, Sethi G, Krishnan K, Aggarwal BB. {gamma}-Tocotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. J Biol Chem. 2007;282:809–20.[Abstract/Free Full Text]

14. Eitsuka T, Nakagawa K, Miyazawa T. Down-regulation of telomerase activity in DLD-1 human colorectal adenocarcinoma cells by tocotrienol. Biochem Biophys Res Commun. 2006;348:170–5.[Medline]

15. Inokuchi H, Hirokane H, Tsuzuki T, Nakagawa K, Igarashi M, Miyazawa T. Anti-angiogenic activity of tocotrienol. Biosci Biotechnol Biochem. 2003;67:1623–7.[Medline]

16. Miyazawa T, Inokuchi H, Hirokane H, Tsuzuki T, Nakagawa K, Igarashi M. Anti-angiogenic potential of tocotrienol in vitro. Biochemistry (Mosc). 2004;69:67–9.[Medline]

17. Mizushina Y, Nakagawa K, Shibata A, Awata Y, Kuriyama I, Shimazaki N, Koiwai O, Uchiyama Y, Sakaguchi K, et al. Inhibitory effect of tocotrienol on eukaryotic DNA polymerase {lambda} and angiogenesis. Biochem Biophys Res Commun. 2006;339:949–55.[Medline]

18. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235:442–7.[Abstract/Free Full Text]

19. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841–4.[Medline]

20. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol. 2002;20:3906–27.[Abstract/Free Full Text]

21. Cox MC, Permenter M, Figg WD. Angiogenesis and prostate cancer: important laboratory and clinical findings. Curr Oncol Rep. 2005;7:215–9.[Medline]

22. Tiidus PM, Houston ME. Vitamin E status does not affect the responses to exercise training and acute exercise in female rats. J Nutr. 1993;123:834–40.[Abstract/Free Full Text]

23. Yonekura K, Basaki Y, Chikahisa L, Okabe S, Miyadera K, Yamada Y. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res. 1999;5:2185–91.[Abstract/Free Full Text]

24. Ribatti D, Vacca A, Roncali L, Dammacco F. The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Int J Dev Biol. 1996;40:1189–97.[Medline]

25. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull. 1996;19:1518–20.[Medline]

26. Hsu PP, Li S, Li YS, Usami S, Ratcliffe A, Wang X, Chien S. Effects of flow patterns on endothelial cell migration into a zone of mechanical denudation. Biochem Biophys Res Commun. 2001;285:751–9.[Medline]

27. Tsuzuki T, Kambe T, Shibata A, Kawakami Y, Nakagawa K, Miyazawa T. Conjugated EPA activates mutant p53 via lipid peroxidation and induces p53-dependent apoptosis in DLD-1 colorectal adenocarcinoma human cells. Biochim Biophys Acta. 2007;1771:20–30.[Medline]

28. Thaloor D, Singh AK, Sidhu GS, Prasad PV, Kleinman HK, Maheshwari RK. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell Growth Differ. 1998;9:305–12.[Abstract]

29. Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature. 1999;398:381.[Medline]

30. Cai T, Fassina G, Morini M, Aluigi MG, Masiello L, Fontanini G, D'Agostini F, De Flora S, Noonan DM, Albini A. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab Invest. 1999;79:1151–9.[Medline]

31. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1{alpha},25-dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo. Circ Res. 2000;87:214–20.[Abstract/Free Full Text]

32. Masso-Welch PA, Zangani D, Ip C, Vaughan MM, Shoemaker S, Ramirez RA, Ip MM. Inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid. Cancer Res. 2002;62:4383–9.[Abstract/Free Full Text]

33. Tsuzuki T, Shibata A, Kawakami Y, Nakagawa K, Miyazawa T. Conjugated eicosapentaenoic acid inhibits vascular endothelial growth factor-induced angiogenesis by suppressing the migration of human umbilical vein endothelial cells. J Nutr. 2007;137:641–6.[Abstract/Free Full Text]

34. Staton CA, Stribbling SM, Tazzyman S, Hughes R, Brown NJ, Lewis CE. Current methods for assaying angiogenesis in vitro and in vivo. Int J Exp Pathol. 2004;85:233–48.[Medline]

35. He L, Mo H, Hadisusilo S, Qureshi AA, Elson CE. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr. 1997;127:668–74.[Abstract/Free Full Text]

36. Ribatti D, Vacca A, Roncali L, Dammacco F. The chick embryo chorioallantoic membrane as a model for in vivo research on anti-angiogenesis. Curr Pharm Biotechnol. 2000;1:73–82.[Medline]

37. Kawakami Y, Tsuzuki T, Nakagawa K, Miyazawa T. Distribution of tocotrienols in rats fed a rice bran tocotrienol concentrate. Biosci Biotechnol Biochem. 2007;71:464–71.[Medline]

38. Marsh SA, Coombes JS. Vitamin E and {alpha}-lipoic acid supplementation increase bleeding tendency via an intrinsic coagulation pathway. Clin Appl Thromb Hemost. 2006;12:169–73.[Abstract/Free Full Text]

39. Samant GV, Sylvester PW. {gamma}-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells. Cell Prolif. 2006;39:563–74.[Medline]

40. Toker A. Protein kinases as mediators of phosphoinositide 3-kinase signaling. Mol Pharmacol. 2000;57:652–8.[Free Full Text]

41. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16:159–78.[Medline]

42. Chavakis E, Dimmeler S. Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler Thromb Vasc Biol. 2002;22:887–93.[Abstract/Free Full Text]

43. Traber MG, Packer L.Vitamin E: beyond antioxidant function. Am J Clin Nutr. 1995;62:1501S–9S.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
 J. Nutr.Home page
H. Uto-Kondo, R. Ohmori, C. Kiyose, Y. Kishimoto, H. Saito, O. Igarashi, and K. Kondo
Tocotrienol Suppresses Adipocyte Differentiation and Akt Phosphorylation in 3T3-L1 Preadipocytes
J. Nutr., January 1, 2009; 139(1): 51 - 57.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
A. Shibata, K. Nakagawa, P. Sookwong, T. Tsuduki, S. Tomita, H. Shirakawa, M. Komai, and T. Miyazawa
Tocotrienol Inhibits Secretion of Angiogenic Factors from Human Colorectal Adenocarcinoma Cells by Suppressing Hypoxia-Inducible Factor-1{alpha}
J. Nutr., November 1, 2008; 138(11): 2136 - 2142.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakagawa, K.
Right arrow Articles by Miyazawa, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakagawa, K.
Right arrow Articles by Miyazawa, T.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Copyright © 2007 by American Society for Nutrition